The use of PCA3 in the diagnosis of prostate cancer

Nature Reviews Urology

Volumn 6, Issue 5, 2009, Pages 255-261

  Hessels, Daphne ^a   Schalken, Jack A ^b  

^a NovioGendix   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE CANCER GENE 3 PROTEIN; PROSTATE PROTEIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSMEMBRANE SERINE PROTEINASE 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; GENE FUSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HIGH RISK POPULATION; HUMAN; MALIGNANT TRANSFORMATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URINALYSIS; BIOSYNTHESIS; CELL TRANSFORMATION; EPITHELIUM; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TISSUE DISTRIBUTION; URINE;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; HUMANS; MALE; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 70449533255     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.40     Document Type: Review

References (27)

1. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Ferlay, J. et al. estimates of the cancer incidence and mortality in europe in 2006. Ann. Oncol. 18, 581-592 (2007).
3. roddam, A. W. et al. Use of prostate-specific antigen (PsA) isoforms for the detection of prostate cancer in men with a PsA level of 2-10 ng/ml: systematic review and metaanalysis. Eur. Urol. 4, 386-399 (2005).
4. Hessels, D. et al. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev. Mol. Diagn. 4, 513-526 (2004).
5. Hessels, D. et al. Molecular Diagnostics in Prostate Cancer. EAU Update Series 3, 200-213 (2005).
6. Bussemakers, M. J. et al. DD3: a new prostatespecific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979 (1999).
7. de Kok, J. B. et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 62, 2695-2698 (2002).
8. Hessels, D. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8-15 (2003).
9. schalken, J. A. et al. New targets for therapy in prostate cancer: differential display code 3 (DD3 [PCA3]), a highly prostate cancer-specific gene. Urology 62 (5 Suppl. 1), 34-43 (2003).
10. iwakiri, J. et al. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J. Urol. 149, 783-786 (1993).
11. Meng, F. J. et al. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol. Biomarkers Prev. 11, 305-309 (2002).
12. van Gils, M. P. et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67, 881-887 (2007).
13. van Gils, M. P. et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 13, 939-943 (2007).
14. Groskopf, J. et al. APTiMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52, 1089-1095 (2006).
15. sokoll, L. J. et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin. Chim. Acta 389, 1-6 (2008).
16. shappell, s. B. et al. PCA3 urine mrNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73, 363-368 (2008).
17. Marks, L. S. et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69, 532-535 (2007).
18. Deras, i. L. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179, 1587-1592 (2008).
19. Haese, A. et al. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur. Urol. 54, 1081-1088 (2008).
20. Ankerst, D. P. et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol. 180, 1303-1308 (2008).
21. Tomlins, s. A. et al. recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
22. Tomlins, s. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396-3400 (2006).
23. Hessels, D. et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103-5108 (2007).
24. Laxman, B. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645-649 (2008).
25. van Gils, M. P. et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68, 1215-1222 (2008).
26. Nakanishi, H. et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 179, 1804-1809 (2008).
27. whitman, E. J. et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 180, 1975-1978 (2008).